{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T22:21:35Z","timestamp":1778538095488,"version":"3.51.4"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2018,3,27]],"date-time":"2018-03-27T00:00:00Z","timestamp":1522108800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1007\/s00213-018-4881-0","type":"journal-article","created":{"date-parts":[[2018,3,27]],"date-time":"2018-03-27T07:10:26Z","timestamp":1522134626000},"page":"1915-1921","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Clozapine-related neutropenia, myocarditis and cardiomyopathy adverse event reports in Australia 1993\u20132014"],"prefix":"10.1007","volume":"235","author":[{"given":"Samantha A.","family":"Hollingworth","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karl","family":"Winckel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nargess","family":"Saiepour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda J.","family":"Wheeler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas","family":"Myles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Siskind","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,3,27]]},"reference":[{"key":"4881_CR1","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.4088\/JCP.09m05785yel","volume":"72","author":"O Agid","year":"2011","unstructured":"Agid O, Arenovich T, Sajeev G, Zipursky RB, Kapur S, Foussias G, Remington G (2011) An algorithm-based approach to first-episode schizophrenia: response rates over 3 prospective antipsychotic trials with a retrospective data analysis. J Clin Psychiatry 72:1439\u20131444","journal-title":"J Clin Psychiatry"},{"issue":"Suppl 12","key":"4881_CR2","first-page":"39","volume":"60","author":"LD Alphs","year":"1999","unstructured":"Alphs LD, Anand R (1999) Clozapine: the commitment to patient safety. J Clin Psychiatry 60(Suppl 12):39\u201342","journal-title":"J Clin Psychiatry"},{"key":"4881_CR3","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1056\/NEJM199307153290303","volume":"329","author":"JM Alvir","year":"1993","unstructured":"Alvir JM, Lieberman JA, Safferman AZ, Schwimmer JL, Schaaf JA (1993) Clozapine-induced agranulocytosis. Incidence and risk factors in the United States. N Engl J Med 329:162\u2013167","journal-title":"N Engl J Med"},{"key":"4881_CR4","doi-asserted-by":"publisher","first-page":"657","DOI":"10.7326\/0003-4819-146-9-200705010-00009","volume":"146","author":"F Andersohn","year":"2007","unstructured":"Andersohn F, Konzen C, Garbe E (2007) Systematic review: agranulocytosis induced by nonchemotherapy drugs. Ann Intern Med 146:657\u2013665","journal-title":"Ann Intern Med"},{"key":"4881_CR5","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.ajhg.2013.01.001","volume":"92","author":"OA Andreassen","year":"2013","unstructured":"Andreassen OA, Djurovic S, Thompson WK, Schork AJ, Kendler KS, O'Donovan MC, Rujescu D, Werge T, van de Bunt M, Morris AP, McCarthy MI, International Consortium for Blood Pressure G, Diabetes Genetics R, Meta-analysis C, Psychiatric Genomics Consortium Schizophrenia Working G, Roddey JC, McEvoy LK, Desikan RS, Dale AM (2013) Improved detection of common variants associated with schizophrenia by leveraging pleiotropy with cardiovascular-disease risk factors. Am J Hum Genet 92:197\u2013209","journal-title":"Am J Hum Genet"},{"key":"4881_CR6","unstructured":"Australian Consensus Panel for Treatment-Refractory Schizophrenia (2010) Targeting treatment-refractory schizophrenia: a multidimensional outcomes approach to the diagnosis and management of incomplete recovery. https:\/\/www.trsconsensus.com.au . Accessed 10 August 2017"},{"key":"4881_CR7","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s00213-013-3076-y","volume":"227","author":"K Beck","year":"2013","unstructured":"Beck K, Howes O (2013) Optimising treatment of refractory schizophrenia. Psychopharmacology 227:373\u2013374","journal-title":"Psychopharmacology"},{"key":"4881_CR8","first-page":"9","volume":"19","author":"Committee on Safety of Medicines","year":"1993","unstructured":"Committee on Safety of Medicines (1993) Myocarditis with antipsychotics: recent cases with clozapine (Clozaril). Curr Prob Pharmacovigil 19:9\u201310","journal-title":"Curr Prob Pharmacovigil"},{"key":"4881_CR9","doi-asserted-by":"publisher","first-page":"55","DOI":"10.2174\/157488612800492681","volume":"7","author":"D Barardis De","year":"2012","unstructured":"De Barardis D, Serroni N, Campanella D, Olivieri L, Ferri F, Carano A, Cavuto M, Martinotti G, Cicconetti A, Piersanti M, Moschetta F, Di Giannantonio M (2012) Update on the adverse effects of clozapine: focus on myocarditis. Curr Drug Saf 7:55\u201362","journal-title":"Curr Drug Saf"},{"key":"4881_CR10","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1002\/j.2051-5545.2011.tb00036.x","volume":"10","author":"M Hert De","year":"2011","unstructured":"De Hert M, Cohen D, Bobes J, Cetkovich-Bakmas M, Leucht S, Ndetei DM, Newcomer JW, Uwakwe R, Asai I, Moller HJ, Gautam S, Detraux J, Correll CU (2011) Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level. World Psychiatry 10:138\u2013151","journal-title":"World Psychiatry"},{"key":"4881_CR11","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/S0140-6736(00)00035-0","volume":"355","author":"S Devarajan","year":"2000","unstructured":"Devarajan S, Kutcher S, Dursun S (2000) Clozapine and sudden death. Lancet 355:841","journal-title":"Lancet"},{"key":"4881_CR12","doi-asserted-by":"publisher","unstructured":"Every-Palmer S, Ellis PM (2017) Clozapine-induced gastrointestinal hypomotility: a 22-year bi-national pharmacovigilance study of serious or fatal \u201cslow gut\u201d reactions, and comparison with international drug safety advice. CNS Drugs doi: https:\/\/doi.org\/10.1007\/s40263-017-0448-6","DOI":"10.1007\/s40263-017-0448-6"},{"key":"4881_CR13","doi-asserted-by":"publisher","first-page":"600","DOI":"10.2353\/ajpath.2008.071008","volume":"173","author":"D Fairweather","year":"2008","unstructured":"Fairweather D, Frisancho-Kiss S, Rose NR (2008) Sex differences in autoimmune disease from a pathological perspective. Am J Pathol 173:600\u2013609","journal-title":"Am J Pathol"},{"key":"4881_CR14","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.cpcardiol.2012.07.003","volume":"38","author":"D Fairweather","year":"2013","unstructured":"Fairweather D, Cooper LT Jr, Blauwet LA (2013) Sex and gender differences in myocarditis and dilated cardiomyopathy. Curr Probl Cardiol 38:7\u201346","journal-title":"Curr Probl Cardiol"},{"key":"4881_CR15","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1055\/s-0035-1554713","volume":"48","author":"T Forrester","year":"2015","unstructured":"Forrester T, Siskind D, Winckel K, Wheeler A, Hollingworth S (2015) Increasing clozapine dispensing trends in Queensland, Australia 2004-2013. Pharmacopsychiatry 48:164\u2013169","journal-title":"Pharmacopsychiatry"},{"key":"4881_CR16","doi-asserted-by":"publisher","first-page":"47","DOI":"10.2165\/00002018-200730010-00005","volume":"30","author":"SJ Haas","year":"2007","unstructured":"Haas SJ, Hill R, Krum H (2007) Clozapine-associated myocarditis: a review of 116 cases of suspected myocarditis associated with the use of clozapine in Australia during 1993-2003. Drug Saf 30:47\u201357","journal-title":"Drug Saf"},{"key":"4881_CR17","doi-asserted-by":"publisher","first-page":"385","DOI":"10.2165\/00002018-200629050-00003","volume":"29","author":"L Hazell","year":"2006","unstructured":"Hazell L, Shakir SA (2006) Under-reporting of adverse drug reactions : a systematic review. Drug Saf 29:385\u2013396","journal-title":"Drug Saf"},{"key":"4881_CR18","first-page":"68","volume":"121","author":"G Hill","year":"2008","unstructured":"Hill G, Harrison-Woolrych M (2008) Clozapine and myocarditis: a case series from the New Zealand intensive medicines monitoring Programme. N Z Med J 121:68\u201374","journal-title":"N Z Med J"},{"key":"4881_CR19","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1111\/j.1447-0349.2007.00506.x","volume":"17","author":"K Hodge","year":"2008","unstructured":"Hodge K, Jespersen S (2008) Side-effects and treatment with clozapine: a comparison between the views of consumers and their clinicians. Int J Ment Health Nurs 17:2\u20138","journal-title":"Int J Ment Health Nurs"},{"key":"4881_CR20","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1136\/bmjinnov-2014-000006","volume":"1","author":"N Holmes","year":"2015","unstructured":"Holmes N, WMiles W, Wheeler A (2015) Development of user-friendly consumer and health professional resources for the antipsychotic clozapine: a New Zealand example. BMJ Innov 1:17\u201321","journal-title":"BMJ Innov"},{"key":"4881_CR21","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1176\/ps.47.1.52","volume":"47","author":"G Honigfeld","year":"1996","unstructured":"Honigfeld G (1996) Effects of the clozapine national registry system on incidence of deaths related to agranulocytosis. Psychiatr Serv 47:52\u201356","journal-title":"Psychiatr Serv"},{"key":"4881_CR22","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/BF00606409","volume":"11","author":"J Idanpaan-Heikklia","year":"1977","unstructured":"Idanpaan-Heikklia J, Alhava E, Olkinuora M, Palva I (1977) Agranulocytosis during treatment with clozapine. Eur J Clin Pharmacol 11:193\u2013198","journal-title":"Eur J Clin Pharmacol"},{"key":"4881_CR23","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1016\/S0140-6736(99)10385-4","volume":"354","author":"JG Kilian","year":"1999","unstructured":"Kilian JG, Kerr K, Lawrence C, Celermajer DS (1999) Myocarditis and cardiomyopathy associated with clozapine. Lancet 354:1841\u20131845","journal-title":"Lancet"},{"key":"4881_CR24","doi-asserted-by":"publisher","first-page":"837","DOI":"10.4088\/JCP.11m07244","volume":"73","author":"L Lahdelma","year":"2012","unstructured":"Lahdelma L, Appelberg B (2012) Clozapine-indduced agranulocytosis in Finland, 1982-2007: long-term monitoring of patients is still warranted. J Clin Psychiatry 73:837\u2013842","journal-title":"J Clin Psychiatry"},{"key":"4881_CR25","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1111\/acps.12700","volume":"135","author":"R Land","year":"2017","unstructured":"Land R, Siskind D, McArdle P, Kisely S, Winckel K, Hollingworth SA (2017) The impact of clozapine on hospital use: a systematic review and meta-analysis. Acta Psychiatr Scand 135:296\u2013309","journal-title":"Acta Psychiatr Scand"},{"key":"4881_CR26","doi-asserted-by":"crossref","first-page":"190","DOI":"10.5694\/j.1326-5377.2009.tb02345.x","volume":"190","author":"J Layland","year":"2009","unstructured":"Layland J, Liew D, Prior D (2009) Clozapine-indiced cardiotoxicity: a clinical update. Med J Aust 190:190\u2013192","journal-title":"Med J Aust"},{"key":"4881_CR27","doi-asserted-by":"publisher","first-page":"175","DOI":"10.3109\/10398562.2010.525646","volume":"19","author":"G Malalagama","year":"2011","unstructured":"Malalagama G, Bastiampillai T, Dhillon R (2011) Clozapine use in Australia. Australas Psychiatry 19:175","journal-title":"Australas Psychiatry"},{"key":"4881_CR28","unstructured":"MedDRA Maintenance and Support Services Organization (2013) Introductory guide MedDRA version 16.1. Chantilly. https:\/\/www.meddra.org\/sites\/default\/files\/guidance\/file\/intguide_16_1_english.pdf . Accessed 22 March 2018"},{"key":"4881_CR29","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1192\/bjp.175.6.576","volume":"175","author":"J Munro","year":"1999","unstructured":"Munro J, O'Sullivan D, Andrews C, Arana A, Mortimer A, Kerwin R (1999) Active monitoring of 12,760 clozapine recipients in the UK and Ireland. Beyond pharmacovigilance. Br J Psychiatry 175:576\u2013580","journal-title":"Br J Psychiatry"},{"key":"4881_CR30","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1111\/j.1600-0447.2011.01710.x","volume":"123","author":"J Nielsen","year":"2011","unstructured":"Nielsen J, Damkier P, Lublin H, Taylor D (2011) Optimizing clozapine treatment. Acta Psychiatr Scand 123:411\u2013422","journal-title":"Acta Psychiatr Scand"},{"key":"4881_CR31","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1080\/14740338.2016.1201475","volume":"15","author":"L Orsolini","year":"2016","unstructured":"Orsolini L, Tomasetti C, Valchera A, Vecchiotti R, Matarazzo I, Vellante F, Iasevoli F, Buonaguro EF, Fornaro M, Fiengo AL, Martinotti G, Mazza M, Perna G, Carano A, De Bartolomeis A, Di Giannantonio M, De Berardis D (2016) An update of safety of clinically used atypical antipsychotics. Expert Opin Drug Saf 15:1329\u20131347","journal-title":"Expert Opin Drug Saf"},{"key":"4881_CR32","doi-asserted-by":"publisher","first-page":"3663","DOI":"10.1007\/s00213-016-4411-x","volume":"233","author":"C Polcwiartek","year":"2016","unstructured":"Polcwiartek C, Vang T, Bruhn CH, Hashemi N, Rosenzweig M, Nielsen J (2016) Diabetic ketoacidosis in patients exposed to antipsychotics: a systematic literature review and analysis of Danish adverse drug event reports. Psychopharmacology 233:3663\u20133672","journal-title":"Psychopharmacology"},{"key":"4881_CR33","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1080\/j.1440-1614.2004.01481.x","volume":"38","author":"J Reinders","year":"2004","unstructured":"Reinders J, Parsonage W, Lange D, Potter JM, Plever S (2004) Clozapine-related myocarditis and cardiomyopathy in an Australian metropolitan psychiatric service. Aust N Z J Psychiatry 38:915\u2013922","journal-title":"Aust N Z J Psychiatry"},{"key":"4881_CR34","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1080\/14740338.2016.1191468","volume":"15","author":"G Remington","year":"2016","unstructured":"Remington G, Lee J, Agid O, Takeuchi H, Foussias G, Hahn M, Fervaha G, Burton L, Powell V (2016) Clozapine\u2019s critical role in treatment resistant schizophrenia: ensuring both safety and use. Expert Opin Drug Saf 15:1193\u20131203","journal-title":"Expert Opin Drug Saf"},{"key":"4881_CR35","doi-asserted-by":"publisher","first-page":"684","DOI":"10.5694\/mja13.10069","volume":"199","author":"J Robertson","year":"2013","unstructured":"Robertson J, Newby DA (2013) Low awareness of adverse drug reaction reporting systems: a consumer survey. Med J Aust 199:684\u2013686","journal-title":"Med J Aust"},{"key":"4881_CR36","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s40264-017-0530-5","volume":"40","author":"L Rolfes","year":"2017","unstructured":"Rolfes L, van Hunsel F, van der Linden L, Taxis K, van Puijenbroek E (2017) The quality of clinical information in adverse drug reaction reports by patients and healthcare professionals: a retrospective comparative analysis. Drug Saf 40:607\u2013614","journal-title":"Drug Saf"},{"key":"4881_CR37","doi-asserted-by":"publisher","first-page":"976","DOI":"10.4088\/JCP.09m05024yel","volume":"71","author":"KJ Ronaldson","year":"2010","unstructured":"Ronaldson KJ, Taylor AJ, Fitzgerald PB, Topliss DJ, Elsik M, McNeil JJ (2010) Diagnostic characteristics of clozapine-induced myocarditis identified by an analysis of 38 cases and 47 controls. J Clin Psychiatry 71:976\u2013981","journal-title":"J Clin Psychiatry"},{"key":"4881_CR38","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.schres.2011.01.017","volume":"128","author":"KJ Ronaldson","year":"2011","unstructured":"Ronaldson KJ, Fitzgerald PB, Taylor AJ, Topliss DJ, McNeil JJ (2011) Clinical course and analysis of ten fatal cases of clozapine-induced myocarditis and comparison with 66 surviving cases. Schizophr Res 128:161\u2013165","journal-title":"Schizophr Res"},{"key":"4881_CR39","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1111\/acps.12416","volume":"132","author":"KJ Ronaldson","year":"2015","unstructured":"Ronaldson KJ, Fitzgerald PB, McNeil JJ (2015) Clozapine-induced myocarditis, a widely overlooked adverse reaction. Acta Psychiatr Scand 132:231\u2013240","journal-title":"Acta Psychiatr Scand"},{"key":"4881_CR40","doi-asserted-by":"crossref","unstructured":"Siskind D, McCartney L, Kisely, S (2017a) Clozapine in treatment-resistant schizophrenia, author\u2019s reply. Br J Psychiatry 210:299\u2013300","DOI":"10.1192\/bjp.210.4.299a"},{"key":"4881_CR41","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1017\/S2045796016000305","volume":"26","author":"DJ Siskind","year":"2017","unstructured":"Siskind DJ, Harris M, Phillipou A, Morgan VA, Waterreus A, Galletly C, Carr VJ, Harvey C, Castle D (2017b) Clozapine users in Australia: their characteristics and experiences of care based on data from the 2010 National Survey of High Impact Psychosis. Epidemiol Psychiatr Sci 26:325\u2013337","journal-title":"Epidemiol Psychiatr Sci"},{"key":"4881_CR42","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/S0140-6736(09)60742-X","volume":"374","author":"J Tiihonen","year":"2009","unstructured":"Tiihonen J, L\u00f6nnqvist J, Wahlbeck K, Klaukka T, Niskanen L, Tanskanen A, Haukka J (2009) 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet 374:620\u2013627","journal-title":"Lancet"},{"key":"4881_CR43","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1097\/00001648-199711000-00014","volume":"8","author":"AM Walker","year":"1997","unstructured":"Walker AM, Lanza LL, Arellano F, Rothman KJ (1997) Mortality in current and former users of clozapine. Epidemiology 8:671\u2013677","journal-title":"Epidemiology"},{"key":"4881_CR44","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1176\/appi.ajp.2017.16091097","volume":"174","author":"T Wimberley","year":"2017","unstructured":"Wimberley T, MacCabe JH, Laursen TM, Sorensen HJ, Astrup A, Horsdal HT, Gasse C, Stovring H (2017) Mortality and self-harm in association with clozapine in treatment-resistant schizophrenia. Am J Psychiatry 174:990\u2013998","journal-title":"Am J Psychiatry"},{"key":"4881_CR45","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1177\/0004867414554269","volume":"49","author":"K Winckel","year":"2015","unstructured":"Winckel K, Siskind D, Hollingworth S, Wheeler A (2015) Clozapine-induced myocarditis: separating the wheat from the chaff. Aust N Z J Psychiatry 49:188","journal-title":"Aust N Z J Psychiatry"}],"updated-by":[{"DOI":"10.1007\/s00213-018-4909-5","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2018,4,23]],"date-time":"2018-04-23T00:00:00Z","timestamp":1524441600000}}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00213-018-4881-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-018-4881-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-018-4881-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,13]],"date-time":"2019-10-13T13:44:53Z","timestamp":1570974293000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00213-018-4881-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,27]]},"references-count":45,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["4881"],"URL":"https:\/\/doi.org\/10.1007\/s00213-018-4881-0","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s00213-018-4909-5","asserted-by":"object"}]},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,27]]},"assertion":[{"value":"10 August 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2018","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors would like to change the statement found in the results section of the abstract from \"There were five reported deaths from neutropenia and cardiomyopathy.\" to \"There were five, 13, and two reported deaths from neutropenia, myocarditis, and cardiomyopathy, respectively.\"","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors report no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"No ethical approval was required as we used only secondary de-identified data sources.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}